Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update

Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 07, 2020 ...
March 12, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update

Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
February 28, 2020 16:08 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
February 05, 2020 12:45 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Reverse Stock Split

HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for...
January 31, 2020 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, Jan. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
January 24, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

HOUSTON, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1...
January 21, 2020 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

Houston manufacturing facility and portions of Bellicum’s Technical Operations and Quality staff to be acquired by MD Anderson Current and future GoCAR™ product candidates to be manufactured by MD...
October 30, 2019 07:30 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update

- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT - HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
June 01, 2019 09:00 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting

Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...
May 15, 2019 16:05 ET | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting

HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...